端粒酶活性的调节及其在肿瘤基因治疗中的研究进展  

Regulation of telomerase activity and gene therapy for cancer

作　　者：李倩倩[1] 邓志华[1] 

机构地区：[1]山西医科大学第二医院消化科,太原030001

出　　处：《国际肿瘤学杂志》2011年第1期17-20,共4页Journal of International Oncology

基　　金：国家自然科学基金资助项目（30672405）

摘　　要：hTERT基因启动子是具有肿瘤特异性的启动子，受多种因子的调控。染色质结构经DNA甲基化或核小体组蛋白修饰被认为是hTERT启动子重要的调控。新近研究发现细胞因子糖原合酶激酶-3、巨噬细胞集落刺激因子受体1、骨诱导因子-7、转录因子c-myc抑制剂、转化生长因子β、环戊烯酮前列腺素以不同方式调控hTERT的活性。端粒酶特异性的复制腺病毒Telomelysin已应用于临床，基于hTERT的各种基因治疗也在不断的研究中。The hTERT gene promoter is a tumor-specific promoter, regulated by a number of factors. Modulation of the chromatin structure via DNA methylation or histone acetylation plays an important role in regulating the hTERT promoter. Recent study also found that glycogen synthase kinase -3 cytokines, macrophage colony-stimulating factor receptor 1, bone inducing factor -7, transcription factors c-myc inhibitor, transforming growth factor β, cyclopentenone prostaglandin regulate the activity of hTERT through various pathways. Telomelysin, the telomerase-specific replication competent oncolytic adenovirus, has been used in clinical settings. Various gene therapies based on hTERT are current under-way.

关 键 词：肿瘤 端粒酶 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]